Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Summary

Johnson & Johnson is exiting the obesity market, a $100 billion market opportunity, while Eli Lilly continues to compete in this space. The article questions whether J&J's strategic withdrawal could position it as a better long-term investment compared to Lilly.